Table 1.

Description of study sites included in the analysis

Study nameStudy abbreviationCountryStudy typeYears of collectionNumber of controlsNumber of casesSerousaMucinousEndometrioidClear cellOtherb
Australian Ovarian Cancer StudyAUSAustraliaPopulation-based2002–2006112210036163913068150
Diseases of the Ovary and their Evaluation StudyDOVUSAPopulation-based2002–200560453030318843095
German Ovarian Cancer StudyGERGermanyPopulation-based1993–19964332031062122648
Hawaii Ovarian Cancer StudyHAWUSAPopulation-based1993–20081708143313616
Novel Risk Factors and Potential Early Detection Markers for Ovarian CancerHOPUSAPopulation-based2003–200938838522019533162
Malignant Ovarian Cancer StudyMALDenmarkPopulation-based1994–199955144527443563339
Mayo Clinic Ovarian Cancer Case Control StudycMAYUSAClinic-based2000–200742231920511632218
North Carolina Ovarian Cancer StudyNCOUSAPopulation-based1999–200865549329320815841
Nijmegen Ovarian Cancer StudyNTHNetherlandsHospital-based200857724310030601835
Polish Ovarian Cancer Case Control StudycPOLPolandPopulation-based2000–200322823810823531341
Family Registry for Ovarian Cancer and Genetic EpidemiologycSTAUSAPopulation-based1997–200141329518418382332
University of California, Irvine Ovarian Cancer StudycUCIUSAPopulation-based1993–200549428016717462129
United Kingdom Ovarian Cancer Population StudycUKOUnited KingdomHospital-based2006–2010852710359711217188
University of Southern California, Study of Lifestyle and Women's HealthUSCUSAPopulation-based1993–200546534118326441573
Total:737455663161359864415767
  • a73.4% high-grade, 7.9% low-grade, 18.7% grade unknown.

  • bIncludes mixed cell, other specified epithelial ovarian cancer, undifferentiated/poorly differentiated epithelial, and unknown but known to be epithelial.

  • cMissing data for nongenetic variables (MAY missing tubal ligation, UCI missing 30% tubal ligation, POL and STA missing endometriosis, UKO >20% missing oral contraceptive use, endometriosis, tubal ligation, and parity).